Hansoh Pharmaceutical Group Company Limited (3692.HK)
HKD 24.4
(1.24%)
HKD 24.4
(1.24%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 10.1 Billion CNY | 7.69% |
| 2022 | 9.38 Billion CNY | -5.56% |
| 2021 | 9.93 Billion CNY | 14.33% |
| 2020 | 8.69 Billion CNY | 0.09% |
| 2019 | 8.68 Billion CNY | 12.44% |
| 2018 | 7.72 Billion CNY | 24.84% |
| 2017 | 6.18 Billion CNY | 13.85% |
| 2016 | 5.43 Billion CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 6.5 Billion CNY | 0.0% |
| 2023 FY | 10.1 Billion CNY | 7.69% |
| 2023 Q2 | 4.51 Billion CNY | 0.0% |
| 2023 Q4 | 5.59 Billion CNY | 0.0% |
| 2022 Q4 | 4.94 Billion CNY | 0.0% |
| 2022 Q2 | 4.43 Billion CNY | 0.0% |
| 2022 FY | 9.38 Billion CNY | -5.56% |
| 2021 FY | 9.93 Billion CNY | 14.33% |
| 2021 Q2 | 4.4 Billion CNY | 0.0% |
| 2021 Q4 | 5.53 Billion CNY | 0.0% |
| 2020 FY | 8.69 Billion CNY | 0.09% |
| 2020 Q4 | 4.71 Billion CNY | 0.0% |
| 2020 Q2 | 3.97 Billion CNY | 0.0% |
| 2019 Q2 | 4.59 Billion CNY | 0.0% |
| 2019 FY | 8.68 Billion CNY | 12.44% |
| 2019 Q4 | 4.08 Billion CNY | 0.0% |
| 2018 FY | 7.72 Billion CNY | 24.84% |
| 2018 Q4 | 3.94 Billion CNY | 0.0% |
| 2018 Q2 | 3.77 Billion CNY | 0.0% |
| 2017 Q4 | 1.93 Billion CNY | 0.0% |
| 2017 Q1 | 1.54 Billion CNY | 0.0% |
| 2017 Q2 | 1.54 Billion CNY | 0.0% |
| 2017 FY | 6.18 Billion CNY | 13.85% |
| 2016 Q4 | 1.54 Billion CNY | 0.0% |
| 2016 Q1 | 1.35 Billion CNY | 0.0% |
| 2016 FY | 5.43 Billion CNY | 0.0% |
| 2016 Q2 | 1.35 Billion CNY | 0.0% |
| 2015 Q4 | 1.35 Billion CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -3798.705% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 4.044% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -16996.697% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -1188.946% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -951.066% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -859.495% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -492.058% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -1148.76% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -2383.368% |
| SSY Group Limited | 6.46 Billion HKD | -56.333% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -1458.231% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -588.365% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 96.263% |